How Assistance Works

Streamlining our patient’s specialty pharmacy experience with unmatched full-service convenience

  • 1. Check Your Coverage/Benefits Verification

    Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.

  • 2. Transfer Prescription to AmeriPharma™

    We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.

  • 3. Prior Authorization

    Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.

  • 4. Copay Assistance & Financial Aid

    We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma™ Specialty Care has secured $55 million in financial assistance for our patients.

  • 5. Nursing Care Coordination

    AmeriPharma™ puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.

  • 6. Delivery Coordination

    Medications are always delivered in strict compliance with the specific requirements for shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.

What Is Ruxience?

Ruxience is a CD20-directed cytolytic antibody used to treat certain autoimmune diseases and types of cancer. It is an FDA- approved biosimilar to Rituxan (rituximab).

Patients should be under the care of a clinician experienced with using rituximab for the specific indication they are being treated for.

Pretreatment immunizations

When feasible, administer appropriate immunizations 4 weeks or more before starting therapy.

Prophylaxis against opportunistic infection and viral reactivation may be warranted during and up to 12 months after completion of rituximab therapy.


The manufacturer’s labeling recommends premedicating about 30 minutes prior to administration with acetaminophen, an antihistamine, and methylprednisolone 100 mg (IV) or equivalent for adults.

What is Ruxience Used to Treat?

Ruxience is used to treat patients with:

  • Non-Hodgkin’s Lymphoma (NHL) 
    • Relapsed or refractory, follicular or low grade, CD20-positive B-cell NHL as a single agent.
    • Previously untreated CD20-positive, follicular, B-cell NHL in combination with first-line chemotherapy. Also used in patients achieving a partial or complete response to a rituximab product in combination with chemotherapy, as a single-agent maintenance therapy.
    • Non-progressing (including stable disease), CD20-positive, low-grade B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy.
    • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or another anthracycline-based chemotherapy regimen.
  • Chronic Lymphocytic Leukemia (CLL) 
    • Previously treated and previously untreated CD20-positive CLL in combination with fludarabine and cyclophosphamide.
  • Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids.
  • Multiple Sclerosis
  • Rheumatoid Arthritis

Copay and Financial Assistance

AmeriPharma™ Specialty Care alleviates financial burdens for patients and their families

  • Advanced software locates funding sources to match you with top-dollar foundation programs

  • One of our copay assistance specialists will assist with the application process

  • Automatic updates will be sent to you and your physician on the status of the funding

Ruxience Dosing Information

Immune thrombocytopenia (alternative agent) (off-label use):

IV dose: 375 mg/m2 once weekly for 4 doses.

Rheumatoid arthritis (Rituxan and rituximab biosimilars) (alternative agent):

Initial IV dose: 1 g once every 2 weeks for 2 doses; subsequent courses of 1 g once every 2 weeks for 2 doses may be administered every 24 weeks or as indicated based on clinical evaluation, but no sooner than every 16 weeks.

Multiple sclerosis (off-label use):

IV dose: 1 g once every 2 weeks for 2 doses; then repeat 1 g once every 6 to 12 months. Alternatively, administer 500 mg to 1 g once every 6 to 12 months.

Myasthenia gravis, refractory or muscle-specific tyrosine kinase antibody-positive (off-label use):

IV dose: 1 g once every 2 weeks for 2 doses or 375 mg/m2 once weekly for 4 weeks; full or partial course may be repeated at preplanned intervals (e.g., 6 months) or as clinically indicated based on symptoms and lymphocyte recovery.

Ruxience Side Effects

  • Feeling tired or weak
  • Headache
  • Upset stomach or throwing up
  • Stomach pain or diarrhea
  • Runny or stuffy nose
  • Muscle spasm
  • Back, muscle, or joint pain
  • Trouble sleeping
  • Night sweats
  • Throat irritation
  • Flushing
  • Anxiety

Insurances Accepted

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.

  • Medicaid logo

Get Started in Minutes

Fill out your information and one of our specialists will call you ASAP.

How Much Can You Save?

Speak with a copay assistance specialist

(877) 778-0318